Bone marrow histopathology in chronic myelogenous leukemia (CML)-evaluation of distinctive features with clinical impact by Thiele, Juergen et al.
Histol Histopathol (1 999) 14: 1241 -1 256 
http://www.ehu.es/histol-histopathol 
Invited Review 
Histology and 
Histopathology 
Bone marrow histopathology in 
chronic myelogenous leukemia (CML)- 
evaluation of distinctive features with clinical impact 
J. Thiele, H.M. Kvasnicka and R. Fischer 
Institute of Pathology, University of Cologne, Cologne, Germany 
Summary .  Bone marrow features in stable-phase 
chronic myelogenous leukemia (CML) are characterized 
by a striking heterogeneity which is determinable by 
appropriate means including representative pre-treatment 
trephine biopsies, immunohistochemistry and morpho- 
metry. Cell lineages involved to a variable extent consist 
not only of neutrophil granulopoiesis, but include also 
megakaryocytes, erythroid precursors, resident macro- 
phages and lymphocytes. Moreover, the stromal 
compartment, in particular reticulin and collagen fibers, 
plays a pivotal role in the disease process. Following 
morphometric analysis significant correlations may be 
calculated between histological parameters and clinical- 
laboratory findings. Relevant interactions are detectable 
between number of megakaryocytes and their precursors 
with fiber density. This finding is in line with the close 
functional relationships between megakaryopoiesis and 
fibroblasts regarding the complex pathomechanisms of 
myelofibrosis. Moreover, other correlations are 
observable between reduction of erythropoiesis or 
increase in fibers with clinical features like anemia, 
percentages of myelo- and erythroblasts in the peripheral 
blood, spleen size or LDH level. These variables are in 
keeping with more advanced stages of CML which 
indicate a transition to myeloid metaplasia and thus exert 
a significant impact on survival. Consequently, the 
different risk profiles of patients are determined by both 
clinical and morphological parameters of predictive 
value. Regarding the latter, extent of myelofibrosis, 
amount of erythroid precursors and numbers of myelo- 
erythroblasts in the peripheral blood are significantly 
associated with prognosis. For this reason, it should be 
mandatory to enter morphological criteria into 
prospective clinical trials on CML, not only for  
diagnotic purpose, but also for a proper evaluation of 
different survival patterns. 
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Introduction 
Amongst the chronic myeloproliferative disorders 
(CMPDs) Philadelphia chromosome-positive (phl+) 
chronic myelogenous leukemia (CML) is not only the 
most frequent subtype, but according to intensive 
molecularbiological investigations and comprehensive 
clinical trials has become the best-characterized entity 
(Kantarjian et al., 1988, 1993; Cline et al., 1992; 
Dickstein and Vardiman, 1995; Spiers, 1995; Giralt et 
al., 1995; Clarkson et al., 1997). This important progress 
in knowledge which has been achieved predominantly 
during the last decade may be responsible for the false 
impression that additional s tudies  involving, in 
particular, morphological features are obsolete. Although 
there is still some disagreement in the literature 
concerning the place of the bone marrow biopsy for 
diagnosis of CML, the increasing use of this technique 
has stimulated more systematically conducted efforts to 
analyse the undisturbed hematopoietic tissue in situ. 
Following pioneering studies (Georgii et al., 1980a,b, 
1990; Burkhardt and Bartl, 1982; Burkhardt et al., 1984; 
Lorand-Metze et al., 1987), a striking heterogeneity of 
bone marrow pathology has been recognized as  a 
common finding in newly diagnosed CML. On the other 
hand, the exact incidence and clinical implication of this 
phenomenon is not well documented (Dickstein and 
Vardiman, 1993). In the light of considerable progress in 
treatment modalities like interferon (Alimena et al., 
1988; Morra et al., 1992; Niederle et al., 1993; Ozer et 
al., 1993; Hehlmann et al., 1994, 1997; Aulitzky et al., 
1995; Kantarjian et al., 1995; Ohnishi et al., 1995; 
Shepard et al., 1996; Richards, 1997; Guilhot et al., 
1997) or bone marrow and stem cell transplantation 
procedures (Gratwohl et al., 1993; McGlave et al., 1994; 
Appelbaum et al., 1995; Van Rhee et al., 1997; Clift and 
Anasetti, 1997; Gale et al., 1998) more attention is being 
paid to prognostic models and risk factors. These 
calculations were aimed at a classification of patients 
into certain groups characterized by different survival 
patterns (Cervantes and Rozman, 1982; Sokal et al., 
1984, 1988; Kantarjian et al., 1985; The Italian Study 
Group, 1991; Hasford et al., 1996, 1998; Cortes et al., 
















